首页> 外文期刊>Materials science & engineering, C. Materials for Biogical applications >Fast dissolving moxifloxacin hydrochloride antibiotic drug from electrospun Eudragit L-100 nonwoven nanofibrous Mats
【24h】

Fast dissolving moxifloxacin hydrochloride antibiotic drug from electrospun Eudragit L-100 nonwoven nanofibrous Mats

机译:来自Electrome eudragit L-100非织造纳米纤维垫的快速溶解莫西沙星抗生素药物

获取原文
获取原文并翻译 | 示例
           

摘要

Antimicrobial electrospun nonwoven Eudragit L-100 nanofibrous mats containing Moxifloxacin hydrochloride (MOX-HCL) were fabricated for fast dissolving drug delivery systems (DDSs) associated with wound infection. The morphological characterization of nanofibers using ESEM revealed that the average diameter of non-woven nanofibrous mats ranges 200-600 nm. The nanofiber showed cylindrical shape with crack on the surface. Differential scanning calorimetric (DSC) and Wide Angle X-ray diffraction (WAXRD) demonstrate that the drug exists in an amorphous state in the nanofibers. Nanofibrous mats were also tested for mechanical strength, contact angle, swelling assay, haemolysis and disintegration test. In vitro disintegration tests demonstrated that the dissolution of Eudragit L-100 fiber mats was within 25 s which was higher compared to the pure drug. The Eudragit nanofibers showed pH-dependent drug release profiles, with slow release at pH 1.2 and burst release (around 30 s) at pH 6.8. The in-vitro quantitative and qualitative antimicrobial assay showed that the developed Eudragit L-100 nanofibrous mats with MOX-HCL concentration of 1%, 5% and 15 wt% exhibited antibacterial activities against both gram positive (Staphylococcus aureus) and gram negative (Escherichia coli) bacteria. The invitro cytotoxicity assay using mouse fibroblast NIH/3T3 cells demonstrated significant biocompatibility of nanofiber mats. As per the results of biological evaluation, Eudragit L-100 nanofibrous mats with 1wt% MOX-HCL could be a suitable substrate for biomedical applications. Eudragit L-100 nanofibrous mats containing Moxifloxacin hydrochloride (MOX-HCL) showed immediate DDSs for localized drug release in the wound infection at slightly acidic or alkaline conditions where faster drug release rate is required for wound healing.
机译:抗微生物Electromun非织造Eyudragit L-100含有Moxifloxacin盐酸盐(MOX-HCl)的纳米纤维垫被制作用于快速溶解与伤口感染相关的药物递送系统(DDS)。 ESEM的纳米纤维的形态学表征显示非织造纳米纤维垫的平均直径范围为200-600nm。纳米纤维显示出圆柱形状,表面裂缝。差分扫描量热(DSC)和广角X射线衍射(WAXRD)表明该药物存在于纳米纤维中的非晶态。还测试了纳米纤维垫的机械强度,接触角,溶胀测定,溶解和崩解试验。体外崩解试验表明,与纯药物相比,Eudragit L-100纤维垫的溶解在25℃内。 Eudragit纳米纤维显示pH依赖性药物释放曲线,pH 1.2的缓慢释放,pH 6.8的爆发释放(约30秒约为30秒。体外定量和定性的抗微生物测定表明,发育的Eudragit L-100纳米纤维垫具有1%,5%和15wt%的Mox-HCl浓度,表现出针对革兰氏阳性(金黄色葡萄球菌)和革兰氏阴性的抗菌活性(大肠杆菌Coli)细菌。使用小鼠成纤维细胞NIH / 3T3细胞的invitro细胞毒性测定表现出纳米纤维垫的显着生物相容性。根据生物学评价的结果,eudragit L-100纳米纤维垫具有1wt%Mox-HCl可以是用于生物医学应用的合适基底。 Eudragit L-100纳米纤维垫含有Moxifloxacin盐酸盐(MOX-HCl)显示出在伤口或碱性条件下的伤口感染中的局部药物释放的即时DDSS,其中伤口愈合需要更快的药物释放速率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号